Status:
COMPLETED
A Study Into the Effectivity and Safety of Firmagon, Prescribed for Treatment of Patients With Advanced Prostate Cancer
Lead Sponsor:
Ferring Pharmaceuticals
Conditions:
Prostate Cancer
Eligibility:
MALE
Brief Summary
Patients eligible for hormone ablation therapy who are prescribed Firmagon will be followed for a maximum of 3 years to estimate the progression free survival. Data on testosteron levels, QoL and LUTS...
Eligibility Criteria
Inclusion
- \- Patients with advanced hormone-dependent prostate carcinoma that are eligible for hormone therapy
Exclusion
- \- Patients with a contraindication for prescription of Firmagon®
Key Trial Info
Start Date :
October 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2015
Estimated Enrollment :
274 Patients enrolled
Trial Details
Trial ID
NCT01215526
Start Date
October 1 2010
End Date
July 1 2015
Last Update
August 19 2015
Active Locations (47)
Enter a location and click search to find clinical trials sorted by distance.
1
Jeroen Bosch Ziekenhuis, locatie Carolus
's-Hertogenbosch, Netherlands
2
Flevoziekenhuis
Almere Stad, Netherlands
3
Bovenij Ziekenhuis
Amsterdam, Netherlands
4
Wilhelminaziekenhuis
Assen, Netherlands